Business, Health Care, Lifestyle, Science

MTF Biologics awards 2024 Grants for Innovation in Allograft Translational Research

Now accepting applications for 2025 grants to accelerate innovation in tissue transplantation     EDISON, N.J. — (BUSINESS WIRE) — MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded

Business, Law & Legal, Sponsored Content

CROX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC announces that Crocs, Inc. investors with substantial losses have opportunity to lead class action lawsuit

NEW YORK — (BUSINESS WIRE) — $CROX #CROX — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Crocs, Inc. (“Crocs” or “the Company”) (NASDAQ: CROX) and

Business, Health Care, Science

ENHERTU® approved in the US as first HER2 directed therapy for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient